235 related articles for article (PubMed ID: 21205945)
1. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
Miyares MA
Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
[TBL] [Abstract][Full Text] [Related]
2. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
4. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Barter P; Rye KA
Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
[TBL] [Abstract][Full Text] [Related]
6. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Goldberg AS; Hegele RA
Drug Des Devel Ther; 2012; 6():251-9. PubMed ID: 23055695
[TBL] [Abstract][Full Text] [Related]
8. Anacetrapib: hope for CETP inhibitors?
Gurfinkel R; Joy TR
Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Shinkai H
Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
[TBL] [Abstract][Full Text] [Related]
12. Safety of CETP inhibition.
Duivenvoorden R; Fayad ZA
Curr Opin Lipidol; 2012 Dec; 23(6):518-24. PubMed ID: 23010697
[TBL] [Abstract][Full Text] [Related]
13. [HDL and CETP in atherogenesis].
Pöss J; Böhm M; Laufs U
Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
[TBL] [Abstract][Full Text] [Related]
14. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
15. Update on CETP inhibition.
Davidson MH
J Clin Lipidol; 2010; 4(5):394-8. PubMed ID: 21122682
[TBL] [Abstract][Full Text] [Related]
16. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
[TBL] [Abstract][Full Text] [Related]
17. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
Page MM; Hooper AJ; Burnett JR
Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
[TBL] [Abstract][Full Text] [Related]
18. Anacetrapib.
Am J Cardiovasc Drugs; 2010; 10(4):267-70. PubMed ID: 20653333
[TBL] [Abstract][Full Text] [Related]
19. Future of cholesteryl ester transfer protein inhibitors.
Rader DJ; deGoma EM
Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
[TBL] [Abstract][Full Text] [Related]
20. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Masson D
Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
